Patent application number | Description | Published |
20090169569 | APO-2L receptor agonist and CPT-11 synergism - Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided. | 07-02-2009 |
20090203104 | TAB Molecules - The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy. | 08-13-2009 |
20110059104 | Apo-2L receptor agonist and CPT-11 synergism - Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided. | 03-10-2011 |
20110160440 | Cab Molecules - The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in diagnosis and therapy. | 06-30-2011 |
20120034243 | Method of Administering an Antibody - Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month. | 02-09-2012 |
20120094357 | TAB MOLECULES - The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy. | 04-19-2012 |
20120107314 | CAB MOLECULES - The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy. | 05-03-2012 |
20120148564 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY - Methods of using SNS-595 for treatment of a subject having cancer with BRCA2 mutation are described. In certain embodiments, the methods comprise administering a therapeutically effective amount of SNS-595 to a subject in need thereof. | 06-14-2012 |
20140186345 | METHOD OF ADMINISTERING AN ANTIBODY - Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month. | 07-03-2014 |